Graham L. Simpson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Graham L. Simpson has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Hannah L. Dexter
GlaxoSmithKline Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, UK
1 shared publicationJennifer A Hughes
1 shared publication- Klara Valko
Bio-Mimetic Chromatography Ltd, Business & Technology Centre, Bessemer Drive, Stevenage, Herts, SG1 2DX, United Kingdom
1 shared publication Praew Thansandote
GlaxoSmithKline Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, UK
1 shared publicationRichard J. Upton
GlaxoSmithKline Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, UK
1 shared publicationRobert M. Harris
GlaxoSmithKline Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, UK
1 shared publication
Latest Publications
- 1 January 2015
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 23 (2) , 322-327
Improving the passive permeability of macrocyclic peptides: Balancing permeability with other physicochemical properties
- 1 January 2015
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 23 (2) , 322-327
Improving the passive permeability of macrocyclic peptides: Balancing permeability with other physicochemical properties
- 1 September 2009
- Vol. 12 (5) , 585-96
Direct small-molecule kinase activation: Novel approaches for a new era of drug discovery.
The pharmaceutical industry has traditionally targeted the inhibition of dysregulated kinases to treat diseases such as cancer and inflammatory disorders. In contrast to the human genome sequencing project, which aimed to identify novel biological targets, the possibility of activating kinases uses known targets in a novel manner. In an approach that is similar to other target classes (eg, GPCRs and nuclear receptors), transient upregulation of kinase function using small molecules has been increasingly demonstrated to lead to favorable disease outcomes. This review discusses direct small-molecule kinase activators: specifically, how these molecules were discovered, characterized, evaluated and developed into drug leads. The choice of potential targets, the mechanisms of activation and the common strategies used to discover activators are also highlighted.
- 1 September 2009
- Vol. 12 (5) , 585-96
Direct small-molecule kinase activation: Novel approaches for a new era of drug discovery.
The pharmaceutical industry has traditionally targeted the inhibition of dysregulated kinases to treat diseases such as cancer and inflammatory disorders. In contrast to the human genome sequencing project, which aimed to identify novel biological targets, the possibility of activating kinases uses known targets in a novel manner. In an approach that is similar to other target classes (eg, GPCRs and nuclear receptors), transient upregulation of kinase function using small molecules has been increasingly demonstrated to lead to favorable disease outcomes. This review discusses direct small-molecule kinase activators: specifically, how these molecules were discovered, characterized, evaluated and developed into drug leads. The choice of potential targets, the mechanisms of activation and the common strategies used to discover activators are also highlighted.